Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 2
2004 3
2005 5
2006 4
2008 2
2009 1
2010 3
2011 2
2012 6
2013 6
2014 10
2015 11
2016 8
2017 9
2018 7
2019 12
2020 7
2021 13
2022 11
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S. John T, et al. Among authors: maemondo m. Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19. Int J Clin Oncol. 2022. PMID: 35182247 Free PMC article. Clinical Trial.
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Kawashima Y, et al. Among authors: maemondo m. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26. Lancet Respir Med. 2022. PMID: 34454653 Clinical Trial.
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
Saito R, Sugawara S, Ko R, Azuma K, Morita R, Maemondo M, Oizumi S, Takahashi K, Kagamu H, Tsubata Y, Seike M, Kikuchi T, Okamoto I, Satoshi M, Asahina H, Tanaka K, Sugio K, Kobayashi K. Saito R, et al. Among authors: maemondo m. Eur J Cancer. 2023 May;185:83-93. doi: 10.1016/j.ejca.2023.02.023. Epub 2023 Mar 2. Eur J Cancer. 2023. PMID: 36966696 Free article. Clinical Trial.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: maemondo m. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
Miyanaga A, Asahina H, Watanabe S, Shukuya T, Tsubata Y, Hosomi Y, Sugawara S, Maemondo M, Okano T, Morita S, Matsuyama K, Kobayashi K, Seike M. Miyanaga A, et al. Among authors: maemondo m. Clin Lung Cancer. 2023 Jun;24(4):371-375. doi: 10.1016/j.cllc.2023.01.008. Epub 2023 Feb 1. Clin Lung Cancer. 2023. PMID: 36849264 Free article. Clinical Trial.
[Anti-RANKL antibody].
Fukuhara T, Maemondo M. Fukuhara T, et al. Among authors: maemondo m. Nihon Rinsho. 2015 Feb;73 Suppl 2:235-9. Nihon Rinsho. 2015. PMID: 25831759 Japanese. No abstract available.
130 results